Trial · NCT04448808
Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol
NCT04448808, Phase 2, Completed, Charite University, Berlin, Germany
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol. Trials, record NCT04448808. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04448808
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol
- NCT number
- NCT04448808
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 170 participants, actual
- Lead sponsor
- Charite University, Berlin, Germany
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- BX-1, Placebo
- First posted
- 2020-06-26
- Last updated
- 2025-08-13
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frequency and intensity of nightmares | 10 weeks | Frequency and intensity of nightmares, measured with the Clinician-Administered PTSD Scale-IV (CAPS-IV) B2 score for the last week, range 0-8. A lower score indicates less frequent and/or intense nightmares. |
| Secondary | Change from baseline of the frequency and intensity of nightmares | 1, 2, 3, 4,6 and 8 weeks | Change from baseline of the frequency and intensity of nightmares, measured with the Clinician-Administered PTSD Scale-IV (CAPS-IV) B2 score for the last week, range 0-8. |
| Secondary | Change from baseline of the CAPS-5 total score | 6 and 10 weeks | Change from baseline of the CAPS-5 total score (overall PTSD symptoms, last week) |
| Secondary | Change from baseline of the Pittsburgh Sleep Quality Index-Addendum for PTSD | 6 and 10 weeks | Change from baseline of the Pittsburgh Sleep Quality Index-Addendum for PTSD (PSQI A) (PTSD related sleep symptoms) |
| Secondary | Change from baseline of the Montgomery-Åsberg Depression Rating Scale | 4 and 10 weeks | Change from baseline of the Montgomery-Åsberg Depression Rating Scale (MADRS, depressive symptoms) |
| Secondary | Weekly mean of change from baseline of daily total sleep time | during 10 weeks | Weekly mean of change from baseline of the patients daily total sleep time (in minutes), assessed with sleep diaries |
| Secondary | Weekly mean of change from baseline of the patients sleep onset latency at night | during 10 weeks | Weekly mean of change from baseline of the patients sleep onset latency at night (in minutes), assessed with sleep diaries |
| Secondary | Weekly mean of change from baseline of the patients recuperation of night sleep | during 10 weeks | Weekly mean of change from baseline of the patients recuperation of night sleep (5-point Likert scale, 1 = very much; 5 = not at all), assessed with sleep diaries |
| Secondary | Weekly mean of change from baseline of the patients time awake at night | during 10 weeks | Weekly mean of change from baseline of the patients time awake at night (in minutes), assessed with sleep diaries |
| Secondary | Weekly mean of change from baseline of the patients number of nightmares last night | during 10 weeks | Weekly mean of change from baseline of the patients number of nightmares last night (0, 1, 3, 4 or more) assessed with sleep diaries |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04448808
GET https://conductscience.org/api/trials/v1/NCT04448808/registered?page=2